Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery

Company Calls Off Inhaled Remdesivir Program

 
• By Alaric DeArment
earnings report
Gilead reported in its second quarter 2021 earnings that its HIV business was showing signs of recovery from its pandemic-induced decline • Source: Shutterstock

More from Earnings

More from Business